(Total Views: 895)
Posted On: 06/05/2020 3:47:13 AM
Post# of 153888
Disease progression COVID-19
In the mild/moderate trial the primary outcome is clinical improvement. This is also the secondary outcome for severe/critical.
I ran across a study, mild/moderate patients had a variety of treatments (antiviral therapy combined with as needed antibiotics, expectorant, Chinese patent medicines, low flow oxygen etc.) That would seem to be close to using placebo. 19.6% progressed to higher severity. With severe/critical patients similar medicinal treatments and low flow oxygen to ventilators. In those cases progression was 27.8% severe, 66.7% critical.
https://erj.ersjournals.com/content/early/202...00990-2020
Will leronlimab's results be statistically significant? I believe so. If one goes by the 19.6% progression (which does not include stable disease) the expected number of moderate patients on placebo in the trial who progress would be expected to be 4 (58 patients). With no progression/reversal in leronlimab and 4 progression in placebo the P value = 0.0394.
If using severe only 27.8% progression and 51 patients, 5 patients in the progression arm would progress. With no progression/reversal in leronlimab and 5 progression in placebo the P value= 0.0241.
In the mild/moderate trial the primary outcome is clinical improvement. This is also the secondary outcome for severe/critical.
I ran across a study, mild/moderate patients had a variety of treatments (antiviral therapy combined with as needed antibiotics, expectorant, Chinese patent medicines, low flow oxygen etc.) That would seem to be close to using placebo. 19.6% progressed to higher severity. With severe/critical patients similar medicinal treatments and low flow oxygen to ventilators. In those cases progression was 27.8% severe, 66.7% critical.
https://erj.ersjournals.com/content/early/202...00990-2020
Will leronlimab's results be statistically significant? I believe so. If one goes by the 19.6% progression (which does not include stable disease) the expected number of moderate patients on placebo in the trial who progress would be expected to be 4 (58 patients). With no progression/reversal in leronlimab and 4 progression in placebo the P value = 0.0394.
If using severe only 27.8% progression and 51 patients, 5 patients in the progression arm would progress. With no progression/reversal in leronlimab and 5 progression in placebo the P value= 0.0241.
(8)
(0)
